Publications by authors named "Andrea Formella"

Claim this Profile
A
Apomorphine differentially engages the cAMP and β-arrestin signaling pathways relative to dopamine at human dopamine receptors.
Brittney Yegla, Jonathan Rubin, Mindy Grall, Andrea Formella, Peter Jenner

J Neural Transm (Vienna)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.
Stuart H Isaacson, Alberto J Espay, Rajesh Pahwa, Pinky Agarwal, Holly A Shill, Andrea E Formella

J Parkinsons Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Ann Childress, Andrew J Cutler, Lenard A Adler, Nicholas Fry, Kobby Asubonteng, Andrea Formella

CNS Drugs· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Huperzine A suppresses absence seizures in the genetic absence epilepsy rat from Strasbourg (GAERS) model of genetic generalized epilepsy with absence seizures.
Pablo M Casillas-Espinosa, Jennie Garcia-Olivares, Rui Li, Crystal Li, Chungping Yu, Andrea E Formella

Epilepsia Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-release amantadine for OFF-related dystonia in Parkinson's disease.
Alberto J Espay, Jill L Ostrem, Andrea E Formella, Caroline M Tanner

Parkinsonism Relat Disord· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
Rajesh Pahwa, Susan Fox, Robert A Hauser, Stuart Isaacson, Judy Lytle, Andrea E Formella

Front Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
Robert A Hauser, Judy Lytle, Andrea E Formella, Caroline M Tanner

NPJ Parkinsons Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia.
Robert A Hauser, Shyamal H Mehta, Daniel Kremens, Dustin Chernick, Andrea E Formella

Neurol Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.
Robert A Hauser, Santosh Goud, Andrea E Formella

Clin Park Relat Disord· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amantadine ER (Gocovri) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease.
Robert A Hauser, Ryan R Walsh, Rajesh Pahwa, Dustin Chernick, Andrea E Formella

Front Neurol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Flora M Hammond, William Sauve, Fred Ledon, Charles Davis, Andrea E Formella

PM R· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.
Richard D Zorowitz, David N Alexander, Andrea E Formella, Fred Ledon, Charles Davis

PM R· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Flora M Hammond, David N Alexander, Andrew J Cutler, Stephen D'Amico, Rachelle S Doody, Andrea E Formella

BMC Neurol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Flora M Hammond, David N Alexander, Andrew J Cutler, Stephen D'Amico, Rachelle S Doody, Andrea E Formella

BMC Neurol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Gary L Pattee, James P Wymer, Catherine Lomen-Hoerth, Stanley H Appel, Andrea E Formella

Curr Med Res Opin· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pseudobulbar affect: burden of illness in the USA.
Jennifer Colamonico, Andrea Formella, Walter Bradley

Adv Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis